

January 15, 1990





# Cancer Research

OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH

VOLUME 50 • NO. 2 • PP 221-450

ISSN 0008-5472 • CNREA 8



New Deadlines for Submission of  
AACR Membership Applications—  
See Page 448.

**THE INTERNATIONAL SOCIETY FOR DIFFERENTIATION AND  
THE CANADIAN SOCIETY FOR CELL BIOLOGY**

*present*

**THE SIXTH INTERNATIONAL CONFERENCE ON  
DIFFERENTIATION OF NORMAL AND NEOPLASTIC CELLS**

July 29 - August 2, 1990

University of British Columbia  
Vancouver, B.C., Canada

**ORGANIZING COMMITTEE**

N. Auersperg, <i>Vancouver</i>	M. DiBerardino, <i>Philadelphia</i>	C. Markert, <i>Raleigh</i>	G. Poste, <i>Philadelphia</i>
M.J. Bissell, <i>Berkeley</i>	C.J. Eaves, <i>Vancouver</i>	R.G. McKinnell, <i>St. Paul</i>	J.W. Schrader, <i>Vancouver</i>
L. Browder, <i>Calgary</i>	I.J. Fidler, <i>Houston</i>	T.S. Okada, <i>Okazaki</i>	S. Schrader, <i>Vancouver</i>
S. Dedhar, <i>Vancouver</i>	W.W. Franke, <i>Heidelberg</i>	G.B. Pierce, <i>Boulder</i>	D. Tarin, <i>Oxford</i>

**SCIENTIFIC PROGRAM**

**LECTURERS**

A. Bernstein, *Toronto*; M.J. Bissell, *Berkeley*; I.W. Dawid, *Bethesda*; W.W. Franke, *Heidelberg*; H. Harris, *Oxford*; P. Iannaccone, *Chicago*; C. Markert, *Raleigh*; T.S. Okada, *Okazaki*; G.B. Pierce, *Boulder*; G. Poste, *Philadelphia*; R.E. Scott, *Rochester*; J.R. Smith, *Houston*; M. Tacheichi, *Kyoto*; D. Tarin, *Oxford*; J.P. Thiery, *Paris*.

**SYMPOSIA (Chairpersons in brackets)**

**Suppression and Reversion of Malignancy**

(E. Stanbridge, *Irvine*) F. Meins, Jr., *Basel*; G. Klein, *Stockholm*;  
W.K. Lee, *San Diego*; P.J. Bryant, *Irvine*.

**Genomic Imprinting and Reversal**

(M.A. DiBerardino, *Philadelphia*) R.G. McKinnell, *St. Paul*; S.  
Rao, *Chicago*; N. First, *Madison*; V. Schmid, *Basel*.

**Extracellular Matrix**

(M. Höök, *Birmingham*) S. Dedhar, *Vancouver*; E.A. Turley,  
*Calgary*; Wm. G. Carter, *Seattle*; H.K. Kleinman, *Bethesda*.

**Signal Transduction, Growth Factors,**

**Second Messengers**

(M.B. Sporn, *Bethesda*) J. Schrader, *Vancouver*;  
R. Derynck, *San Francisco*; P. Besmer, *New York*; M.B. Sporn,  
*Bethesda*.

**Pattern Formation**

(L. Harrison, *Vancouver*) P. Gruss, *Goettingen-Nikolausberg*; T.  
Sachs, *Jerusalem*; E. Larsen, *Toronto*; L. Harrison, *Vancouver*.

**Differentiation and Cancer: The Hematopoietic System**

(C.J. Eaves, *Vancouver*) T.M. Dexter, *Manchester*; Ch. Sherr,  
*Memphis*; G. Krystal, *Vancouver*; T.W. Mak, *Toronto*.

**Oncogenes and Differentiation**

(M.J. Bissell, *Berkeley*) E.Y. - H.P. Lee, *San Diego*; G. Weeks,  
*Vancouver*; N. Fausto, *Providence*; J. Brugge, *Philadelphia*.

**Differentiation as Therapy for Cancer**

(S. Waxman, *New York*) M.S. Wicha, *Ann Arbor*; J. Schlom,  
*Bethesda*; H.P. Koeffler, *Los Angeles*; S. Waxman, *New York*.

**Regulation of Synthesis and Assembly of Cytoskeletal  
Proteins**

(W.W. Franke, *Heidelberg*) A. Ben Ze'ev, *Rehovot*; D.W.  
Cleveland, *Baltimore*; G. Krohne, *Heidelberg*; T.D. Pollard,  
*Baltimore*.

**Retinoic Acid, Gene Expression and Differentiation**

(M.W. Mc Burney, *Ottawa*) C. Tickle, *London*; M. Petkovich,  
*Kingston*; L. Gudas, *Boston*; T. Muramatsu, *Kagoshima*.

**Metastasis:**

**Current Status of the Seed and Soil Hypothesis**

(D. Tarin, *Oxford*) J.I. Fidler, *Houston*; E.V. Sugarbaker, *Miami*;  
I.R. Hart, *London*; H. Kobayashi, *Sapporo*.

**Epithelial Cell Differentiation**

(T.T. Sun, *New York*) W.W. Franke, *Heidelberg*; L.C. M. Reid,  
*New York*; T.T. Sun, *New York*; D. Louvard, *Paris*.

**Cell and Tissue Interactions**

(G.H. Heppner, *Detroit*) P. D'Amore, *Boston*; G.P. Dotto, *New  
Haven*; J.E. Blalock, *Birmingham*; G.H. Heppner, *Detroit*.

**For information, contact:**

Conference Secretariat, D.N.N.C.  
c/o Venue West Ltd.  
801 - 750 Jervis Street  
Vancouver, B.C., Canada V6E 2A9  
Telephone: (604) 681-5226  
FAX: (604) 681-2503

# New Advances in Cancer Research

*Triton c-erbB-2  
(or HER-2/neu) Antibodies*

Amplification of c-erbB-2 may indicate the progression of some human breast cancers and may be predictive for clinical outcome.

Triton's c-erbB-2 monoclonal and polyclonal antibodies perform in immunohistochemical analysis in formalin-fixed or frozen tissues. Also for FACS, RIPA and Western blot applications.

Triton Biosciences Inc.  
Diagnostics Division  
1501 Harbor Bay Parkway  
Alameda, CA 94501  
1-800-874-8667  
1-800-682-6200  
(CA only)



Triton Biosciences Inc.  
DIAGNOSTICS DIVISION

FOR RESEARCH USE ONLY  
Not for use in diagnostic procedures.

## The National Neurofibromatosis Foundation *announces the availability of* Young Investigator Awards

which will provide salary support not to exceed \$35,000 annually for period up to two years and

### Research Grants

which will provide up to \$50,000 for up to two years for research on the cause and treatment of neurofibromatosis.

The deadline for filing applications for funding beginning July 1, 1990, is April 2, 1990.

For information on applications please contact:

The National Neurofibromatosis Foundation  
141 Fifth Avenue, Suite 7-S  
New York, New York 10010  
212-460-8980  
1-800-323-7938 Outside New York State  
Fax# 212-529-6094

PUBLIC HEALTH SERVICE  
NATIONAL INSTITUTES OF HEALTH  
NATIONAL CANCER INSTITUTE

A Senior Executive Service Vacancy

## ASSOCIATE DIRECTOR

Cancer Prevention Research Program  
Division Of Cancer Prevention And Control

Location: Rockville, Maryland

The Associate Director, Cancer Prevention Research Program, will be responsible for the overall planning, coordination and monitoring of a worldwide Cancer Prevention Program designed to provide prompt evaluation of new leads in cancer prevention. The Cancer Prevention Research Program has a staff of approximately 46 who administer a large intramural and extramural program with a budget of approximately \$36 million annually.

This is a Civil Service position in the Senior Executive Service (SES) with an annual salary compensation between ES-1 through ES-4 (currently \$68,700 to \$76,400 per annum). In addition, physicians may be eligible for a Physician's Comparability Allowance up to \$20,000 per year. (Applicants alternatively may be eligible for appointment in the Commissioned Corps of the U.S. Public Health Service.) The individual selected, if not presently in SES, must serve a one-year probationary period.

Applicants must meet the minimum educational requirements for Medical Officer, GS-602. Applicants must further meet established mandatory professional/technical and managerial/executive requirements. Applicants will be further evaluated on the degree to which they possess additional desirable qualifications in the areas of professional/technical qualifications, managerial/executive qualifications, scientific reputation/peer recognition, training and education, and honors and awards. A copy of the requirements may be obtained by contacting Ms. Dolores Guido in the Personnel Management Branch, NCI, at (301) 496-8182.

Applications for Federal Employment (SF-171), are to be sent to the above individual at:

The National Cancer Institute  
Personnel Management Branch  
9000 Rockville Pike  
Building 31, Room 3A19  
Bethesda, Maryland 20892



A current curriculum vitae and bibliography must accompany all applications for entrance into the SES. Resumes are not acceptable applications for entrance into the SES. Public Health Service Commissioned Officers wishing to enter the SES must follow the above procedures. Officers interested in performing the duties of the position within the Commissioned Corps may submit a resume to the above address.

Applications must be received by February 2, 1990.

SELECTION FOR THIS POSITION WILL BE BASED SOLELY ON MERIT, WITH NO DISCRIMINATION FOR NON-MERIT REASONS SUCH AS RACE, COLOR, RELIGION, SEX, NATIONAL ORIGIN, POLITICS, MARITAL STATUS, PHYSICAL HANDICAP, AGE, OR MEMBERSHIP OR NON-MEMBERSHIP IN AN EMPLOYEE ORGANIZATION.

NIH IS AN EQUAL OPPORTUNITY EMPLOYER

KEEP UP WITH THE LATEST DEVELOPMENTS  
IN  
**Cancer Research**

THE OFFICIAL JOURNAL OF  
THE AMERICAN ASSOCIATION FOR CANCER RESEARCH

**Subscribe to *Cancer Research***—the leading citation source of original studies in cancer research and cancer-related biomedical science. Issued semimonthly, *Cancer Research* publishes over 8,000 pages per year that keep you abreast of the most significant and timely findings in your field through the following regular features:

- **The most up-to-date articles** in basic research and clinical and epidemiological investigations by authors from the United States and more than 20 countries
- **Perspectives in Cancer Research**, in which leading investigators explore contemporary and at times controversial topics
- **Supplemental issues** developed from symposia on relevant subjects—the January 1990 Supplement features the *Second Conference on Radioimmunodetection and Radioimmunotherapy of Cancer*.
- **Proceedings of the American Association for Cancer Research**, a special annual issue that offers stimulating new research ideas in abstract form

ORDER THE MOST HIGHLY CITED JOURNAL IN ITS FIELD  
TODAY

-----  
 Yes, I want to keep up with the latest developments in *Cancer Research*. Enter my one-year subscription.

1990 Subscription Rates:     Individual, \$265     Institutional, \$295

Add \$60 for delivery outside the U.S. Subscriptions payable in advance (in US currency or equivalent) to:

WAVERLY PRESS, INC.  
c/o Cancer Research  
428 East Preston St.  
Baltimore, MD 21202

Allow 8 weeks for receipt of first issue.


Name \_\_\_\_\_

Address \_\_\_\_\_

City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_

# COVER LEGEND

---



The vitality of contemporary cancer research and its position in the mainstream of biomedical science is attested to by the awards of the Nobel Prize for Physiology or Medicine for the past two years. Following on the heels of the 1988 award to George Hitchings and Gertrude Elion is the 1989 award to J. Michael Bishop and Harold E. Varmus for their landmark research on oncogenes.

Working together during the past 18 years with the Rous sarcoma viruses, they demonstrated in 1976 [Stehelin, Varmus, Bishop, and Vogt, *Nature (Lond.)*, **260**: 170, 1976] that DNA closely related to the trans-

forming gene of the Rous virus is present in normal avian cells. Following this remarkable and unexpected discovery, they and others have identified over 40 cellular genes which are widespread in eukaryotes and function in growth control in normal cells but, when mutated or amplified, lead to malignant transformation. They believe that the counterpart oncogenes of the transforming retroviruses were acquired by the virus during replication in the host cell. It is now recognized that the proteins encoded by the oncogenes play regulatory roles in the cell as growth factors, receptors, or components of cytoplasmic or nuclear signal mechanisms. Recent reviews are by: H.E. Varmus. Lessons from the life cycle of retroviruses. The Harvey Lectures, Series 83, pp. 35-56. New York: Alan R. Liss, 1989; J. M. Bishop. The Molecular Biology of Oncogenes, *In*: E. Bergsagel and T. W. Mak (eds.), *Molecular Mechanisms and Their Clinical Application in Malignancies*. Proceedings of the 12th Annual Bristol-Myers Symposium on Cancer Research, Ontario Cancer Institute. New York: Academic Press, in press, 1990.

Pictured are: *upper*, J. Michael Bishop, M.D., Professor of Microbiology, Immunology, Biochemistry and Biophysics, Director of the George F. Hooper Research Foundation, and Director of the Program in Biological Sciences, University of California, San Francisco, *lower*, Harold E. Varmus, M.D., American Cancer Society Professor of Molecular Virology and Professor of Microbiology, Immunology, Biochemistry and Biophysics, University of California, San Francisco.

Sidney Weinhouse

## **ANNOUNCING THE NEW EDITOR-IN-CHIEF OF *CANCER RESEARCH***

The January 1, 1990 issue marks the beginning of Carlo M. Croce's tenure as Editor-in-Chief of *Cancer Research*. Dr. Croce is an internationally renowned figure in the cancer research community. Among his many achievements are his outstanding accomplishments in the areas of molecular genetics of human cancer, chromosomes and oncogenes, the discovery of the involvement of immunoglobulin loci and the *c-myc* oncogene in Burkitt's lymphoma, and the identification of the *bcl-2* gene which has already found clinical application in the monitoring of residual disease in treated patients.

Born in Milan, Italy, in 1944, Dr. Croce received his M.D. degree from the University of Rome in 1969. He came to the United States in 1970 to work at the Wistar Institute of Anatomy and Biology in Philadelphia, PA. He was affiliated with Wistar for over 18 years, during which time he served in various capacities from Professor to Associate Director. In 1988, he succeeded Peter N. Magee as Director of Fels Institute for Cancer Research and Molecular Biology, located at Temple University Health Sciences Center in Philadelphia. He now succeeds Dr. Magee as Editor-in-Chief of *Cancer Research*. Dr. Magee held this post since 1980.

On the facing page appears Dr. Croce's first communication to our readers in his new capacity as Editor-in-Chief. The American Association for Cancer Research is delighted that Dr. Croce has undertaken this very important responsibility. Under his leadership, we look forward to the further enhancement of our journal's reputation as the most highly cited cancer journal in the world.